Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7539.092 | 0.0068 | -0.9661 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7540.09 | 0.9067 | 0.6842 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7540.09 | 1.0589 | 1.2112 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7540.09 | 1.0240 | 1.0849 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7540.09 | 0.9337 | 0.7735 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7540.09 | 0.9298 | 0.7603 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7540.09 | 0.6220 | -0.1303 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7540.09 | 0.5981 | -0.1881 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7540.09 | 0.2453 | -0.8299 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7540.09 | 0.8523 | 0.5112 | 0.5702 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7541.091 | 0.9631 | 0.9475 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7541.091 | 1.0229 | 1.0323 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7541.091 | 0.9875 | 0.9823 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7541.091 | 1.0026 | 1.0037 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7541.091 | 1.0095 | 1.0134 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7541.091 | 0.9632 | 0.9476 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7541.091 | 0.6871 | 0.5332 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7541.091 | 0.1783 | -0.4103 | 1.4119 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7541.091 | 0.0041 | -0.9595 | 1.4119 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7542.092 | 1.0397 | 1.0512 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7542.092 | 0.9621 | 0.9504 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7542.092 | 0.9530 | 0.9384 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7542.092 | 0.9165 | 0.8897 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7542.092 | 0.9718 | 0.9632 | 1.5380 | |
| T47D | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7542.092 | 0.8284 | 0.7695 | 1.5380 |